Pasar al contenido principal

ELECTROCHEMICAL IMMUNOSENSOR SYSTEM FOR THE DETECTION OF NEUROACTIVE TRYPTOPHAN METABOLITES. DEVELOPMENT OF IMMUNOREAGENTS AND NANOSTRUCTURED BIOHYBRID SENSING SURFACES.

CTQ2011-29163-C03-01

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2011
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer’s Disease

  • Marrugo-Ramírez, José
  • Rodríguez-Núñez, Montserrat
  • Marco, María Pilar
  • Mir, Mònica
  • Samitier, Josep
Alzheimer’s disease (AD) is a neurodegenerative disorder, characterized by a functional deterioration of the brain. Currently, there are selected biomarkers for its diagnosis in cerebrospinal fluid. However, its extraction has several disadvantages for the patient. Therefore, there is an urgent need for a detection method using sensitive and selective blood-based biomarkers. Kynurenic acid (KYNA) is a potential biomarker candidate for this purpose. The alteration of the KYNA levels in blood has been related with inflammatory processes in the brain, produced as a protective function when neurons are damaged. This paper describes a novel electrochemical immunosensor for KYNA detection, based on successive functionalization multi-electrode array. The resultant sensor was characterized by cyclic voltammetry (CV), chronoamperometry (CA), and electrochemical impedance spectroscopy (EIS). The proposed biosensor detects KYNA within a linear calibration range from 10 pM to 100 nM using CA and EIS, obtaining a limit of detection (LOD) of 16.9 pM and 37.6 pM in buffer, respectively, being the lowest reported LOD for this biomarker. Moreover, to assess our device closer to the real application, the developed immunosensor was also tested under human serum matrix, obtaining an LOD of 391.71 pM for CA and 278.8 pM for EIS with diluted serum., The Nanobioengineering group has support from the Commission for Universities and Research of the Department of Innovation, Universities, and Enterprise of the Generalitat de Catalunya (2017 SGR 1079) and is part of the CERCA Programme/Generalitat de Catalunya. CIBER-BBN is an initiative funded by the VI National R&D&i Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund (CB06/01/0055). The work developed by the Nanobiotechnology for Diagnostics (Nb4D) group has been funded by the Ministry of Science and Innovation (TryKySeNS project, CTQ2011-29163-C03-01), and the Ministry of Economy and Competitiveness (Molecular links between diabetes and neurodegenerative disorders, Integrated Projects of Excellence in CIBER, PIE14/00061). The Nb4D group is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (expedient: 2017 SGR 1441)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Kynurenic acid levels are increased in the CSF of Alzheimer's disease patients

  • González-Sánchez, Marta|||0000-0001-9155-1438
  • Jiménez, Javier
  • Narváez García, Arantzazu|||0000-0001-8141-558X
  • Antequera, Desiree
  • Llamas-Velasco, Sara|||0000-0002-9174-2610
  • Herrero San-Martín, Alejandro
  • Molina Arjona, Jose Antonio
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • Lleó, Alberto|||0000-0002-2568-5478
  • Marco, María Pilar|||0000-0002-4064-1668
  • Rodríguez-Núñez, Montserrat
  • Pérez-Martínez, David Andrés|||0000-0001-5587-0415
  • Villarejo-Galende, Alberto|||0000-0002-6834-7620
  • Bartolome, Fernando|||0000-0001-9322-8933
  • Domínguez, Elena
  • Carro, Eva M.
Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer's disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases.